Catch up on the latest in diabetes tech from Dexcom, Abbott, Roche Diabetes Care, Insulet, Medtronic and Know Labs. Every year, the diabetes community comes together for the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). In this year’s 17th installment, some of the biggest names shared new studies and technologies set to […]
Medtronic
Medtronic highlights global performance of MiniMed 780G automated insulin delivery system
Medtronic (NYSE:MDT) shared new clinical and real-world evidence backing the use of its MiniMed 780G system around the world. Data shared at ATTD 2024 in Florence, Italy, included the largest set of data from early users in the U.S. Results built upon three-year data from more than 100,000 real-world users who outperformed international time in […]
These diabetes devices are set to launch in 2024
The diabetes space continues to innovate, and it doesn’t look like that’s stopping any time soon, with 2024 set to be another banner year. At the end of 2023, we compiled a list of the 10 biggest diabetes technology stories of the year. Some of those stories didn’t end in 2023, though, as a few […]
Medtronic wins CE mark for MiniMed 780G with Simplera Sync disposable, all-in-one CGM
Medtronic (NYSE:MDT) announced today that it received CE mark approval for its MiniMed 780G system with Simplera Sync. Simplera Sync, a disposable, all-in-one continuous glucose monitor (CGM), eliminates the need for fingersticks and overtape. It features an improved user experience at half the size of previous Medtronic sensors with a simple, two-step insertion process. MiniMed […]
The 10 biggest diabetes tech stories from 2023
It was another banner year for diabetes technology, with regulatory approvals, product launches and M&A all playing their part. Diabetes technology’s impressive 12 months marked a major trend across medtech as a whole, too. In 2022, the diabetes space saw plenty of progress from some of its biggest names and this past year proved no […]
Report: There’s still ‘mutual interest’ with EOFlow, Medtronic despite deal falling through
Business Korea reports that EOFlow CEO Kim Jae-jin is leaving the door open with regard to the company’s collapsed deal with Medtronic (NYSE:MDT). Medtronic announced this week that it terminated its $738 million agreement to acquire EOFlow, a maker of insulin patch pumps. The medtech giant cited “multiple breaches” of terms in the agreement as […]
Medtronic nixes $738M deal for insulin patch pump maker EOFlow
Medtronic (NYSE:MDT) filed a Form 8K with the SEC today stating that it terminated its agreement to buy EOFlow. The medtech giant struck a $738 million deal to acquire the Seongnam, South Korea-based insulin patch pump maker in May. EOFlow develops the EOPatch — a tubeless, wearable and fully disposable insulin delivery device. Medtronic’s SEC filing […]
Here’s what diabetes tech companies are doing on World Diabetes Day
Every November, the diabetes community comes together to recognize both National Diabetes Month in the U.S. and World Diabetes Day. World Diabetes Day falls on today, Nov. 14, to mark the birthday of Sir Frederick Banting. Banting discovered the insulin hormone along with Charles Herbert Best in 1922. In an effort to drive awareness and […]
Medtronic brings Blue Balloon Challenge to World Diabetes Day
To mark World Diabetes Day and National Diabetes Month in the U.S., Medtronic (NYSE:MDT) is bringing back its “Blue Balloon Challenge.” Introduced in 2021, the movement encourages people with diabetes to help drive awareness and understanding of the chronic condition. The company instructs people to take a video or photo while bouncing a blue balloon […]
NICE recommends automated insulin delivery tech rollout in UK, Medtronic, Dexcom applaud
An independent committee of the National Institute for Health and Care Excellence (NICE) voiced support for closed-loop insulin delivery. The UK-based institute recommended offering automated insulin delivery (AID) for people whose type 1 diabetes is not controlled with their current device despite best possible management with an insulin pump or real-time or intermittently scanned continuous […]
